Zevra Therapeutics is a clinical-stage biopharma company advancing transformative therapies for serious diseases with a robust pipeline and recent capital raising to fund operations.
Investors might view Zevra Therapeutics as a high-risk, high-reward opportunity given its proprietary pipeline and potential to capture significant value upon regulatory approval of key assets. The company's ability to secure substantial financing inflows suggests confidence from capital markets in the long-term viability of its therapeutic platform. If the current revenue trend stabilizes or accelerates, the stock could experience significant multiple expansion as it transitions toward profitability.
The deteriorating net income trend, worsening from a $-41.5M loss in 2022 to a $-105.5M loss in 2024, raises concerns about the company's path to sustainable cash flow generation. With negative operating cash flow and a massive deficit in retained earnings, Zevra is burning through capital rapidly without a clear horizon for commercial success. The thin equity base relative to liabilities exposes shareholders to high dilution risk if additional funding rounds are required to sustain operations.
Zevra Therapeutics focuses on developing innovative therapeutic solutions primarily within the specialized pharmaceutical and biotechnology markets. The company leverages its pipeline of novel compounds to address unmet medical needs through targeted drug discovery and development programs. Key revenue streams are derived from product sales, research collaborations, and strategic licensing agreements in oncology and other disease areas.
Management has successfully maintained a positive cash balance of $33.8M despite posting a net loss of $105.5M in the latest period, largely funded by significant financing activities totaling $82.1M. While revenue growth slowed from 2023 to 2024, dropping from $27.5M to $23.6M, the company continues to invest heavily in R&D as reflected in high operating expenses of $103.2M and substantial depreciation and amortization of $6.4M. The balance sheet remains under pressure with total liabilities at $138.5M against shareholders' equity of only $39.7M, highlighting the need for sustained cash generation or further dilution.
The global biotechnology sector is characterized by intense competition, long development cycles, and binary outcomes where only a fraction of drugs achieve regulatory approval. Companies in this space often operate with negative earnings initially, relying on venture capital or public markets to fund research until products generate commercial revenue. Regulatory environments remain stringent, requiring substantial investment in clinical trials to demonstrate safety and efficacy before market entry.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $10.5M | $27.5M | $23.6M |
| Cost of Revenue | $343.0K | $2.9M | $7.4M |
| Gross Profit | $10.1M | $24.5M | $16.2M |
| Operating Expenses | $52.6M | $74.1M | $103.2M |
| Operating Income | $-42.5M | $-49.6M | $-87.0M |
| G&A | $15.3M | $34.3M | $54.9M |
| Stock-Based Comp | $4.3M | $6.0M | $14.9M |
| D&A | $944.0K | $1.0M | $6.4M |
| Amortization | — | $800.0K | $6.2M |
| Other OpEx | $37.3M | $39.8M | $48.3M |
| Non-Operating Income | $176.0K | $3.6M | $-3.1M |
| Interest Expense | $335.0K | $1.5M | — |
| Pre-Tax Income | $-42.3M | $-46.0M | $-90.1M |
| Income Tax | $-786.0K | $0 | $15.4M |
| Continuing Ops | $-41.5M | $-46.0M | $-105.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-41.5M | $-46.0M | $-105.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-41.5M | $-46.0M | $-105.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $93.0M | $86.9M | $86.0M |
| Cash & Equivalents | $65.5M | $43.0M | $33.8M |
| Accounts Receivable | $7.2M | $16.1M | $10.2M |
| Inventory | — | $9.8M | $2.0M |
| Prepaid Expenses | $1.9M | $1.8M | $4.1M |
| Other Current Assets | $18.5M | $16.1M | $36.0M |
| Long-Term Assets | $22.5M | $85.4M | $92.1M |
| PP&E (Net) | $794.0K | $736.0K | $356.0K |
| Intangibles | — | $69.2M | $69.0M |
| Goodwill | — | $4.7M | $4.7M |
| Operating Leases | $988.0K | $790.0K | $657.0K |
| Other LT Assets | $20.7M | $9.9M | $17.4M |
| Total Assets | $115.5M | $172.3M | $178.1M |
| Current Liabilities | $11.7M | $73.7M | $34.1M |
| Accounts Payable | $3.6M | $14.0M | $13.1M |
| Current Leases | $480.0K | $543.0K | $420.0K |
| Other Current Liab | $7.6M | $59.2M | $20.6M |
| Long-Term Liabilities | $18.0M | $36.7M | $104.4M |
| Long-Term Debt | — | — | $59.5M |
| LT Operating Leases | $843.0K | $456.0K | $372.0K |
| Other LT Liab | $17.2M | $-1.4M | $30.1M |
| Total Liabilities | $29.7M | $110.5M | $138.5M |
| Shareholders' Equity | $85.8M | $61.9M | $39.7M |
| Retained Earnings | $-308.6M | $-399.8M | $-505.3M |
| AOCI | $113.0K | $-43.0K | $631.0K |
| Treasury Stock | $7.5M | $11.0M | $11.0M |
| Total L&E | $115.5M | $172.3M | $178.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-41.5M | $-46.0M | $-105.5M |
| Non-Cash Adjustments | $13.6M | $-7.3M | $35.0M |
| Working Capital Changes | $9.3M | $19.8M | $845.0K |
| Cash from Operations | $-18.7M | $-33.5M | $-69.7M |
| Capital Expenditures | $93.0K | $296.0K | $0 |
| Cash from Investing | $-36.7M | $-17.4M | $-22.2M |
| Share Buybacks | $4.7M | $3.4M | $0 |
| Cash from Financing | $8.4M | $28.5M | $82.1M |
| FX Effect | $204.0K | $44.0K | $454.0K |
| Net Change in Cash | $-46.9M | $-22.4M | $-9.3M |
| Beginning Cash | $112.3M | $65.5M | $43.0M |
| Ending Cash | $65.5M | $43.0M | $33.8M |
The company's revenue is generated through direct product sales of its therapeutic portfolio, commercial partnerships with external research institutions, and licensing fees or milestones received from collaborative development agreements. Additionally, income is derived from government grants supporting early-stage research initiatives and reimbursement programs for approved therapies in specific niches.
The company faces significant financial risk due to substantial accumulated losses and a large retained earnings deficit of $505.3M, indicating heavy reliance on future profitability or capital markets. Heavy dependence on external financing is evident given the negative cash flow from operations of $69.7M and recent common share issuances of $64.5M to raise liquidity. Clinical trial failures or regulatory rejections could materially impact the value of its intangible assets, which total $69.0M. Market competition from larger pharmaceutical entities may erode potential market share for any approved products.
Zevra Therapeutics possesses a proprietary technology platform that accelerates drug discovery timelines while reducing R&D costs compared to traditional methods. The company benefits from strong intellectual property protection across its key asset classes, providing a defensible moat against generic competition. Its strategic focus on high-need therapeutic areas ensures alignment with favorable regulatory pathways and payer demand.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.